Deltex Medical Regulatory News (DEMG)

7 Jun 2007 07:03

Deltex Medical Group PLC07 June 2007 Deltex Medical Group plc CardioQ reduces complications and length of hospital stay after 'keyhole' surgery 7 June 2007 - Deltex Medical Group plc ("Deltex Medical" or "Company"), the UK'sleading haemodynamic monitoring company, today reports new data on theeffectiveness of CardioQ during minimally invasive surgery. The findings were presented to approximately 500 American surgeons at thisweek's annual meeting of the American Society of Colon and Rectal Surgeons(ASCRS) in St Louis, USA. Miss Sophie Noblett, a UK surgeon, presented for the first time analysis ofthose keyhole surgery patients included in the randomised controlled clinicaltrial from the Freeman Hospital in Newcastle-upon-Tyne published in 2006 andannounced by the Company on 31 August 2006 (Noblett SE, Snowden CP, Shenton BK,Horgan AF. Intraoperative fluid optimisation improves outcome after majorcolorectal surgery. BJS 2006 93; issue 9; 1069-1076). Miss Noblett noted that minimally invasive techniques for bowel surgery aregenerally accepted to shorten lengths of hospital stay and that the aim of heranalysis was to determine whether using CardioQ to optimise fluid delivery insuch patients would further reduce lengths of stay when compared with keyholesurgery patients who had their fluids managed using traditional clinicalpractice. In total, 30 out of 108 patients in the trial were treated using minimallyinvasive surgery ('laparoscopic' or 'keyhole' surgery). Of these 17 had theirfluids managed using the CardioQ. The results showed that CardioQ patients: •tolerated food one day earlier (two days, compared to three days) •experienced fewer post-operative complications (6% compared to 38%) •were able to leave hospital three days earlier (four days compared to seven days) All the above results were, statistically, highly significant. Dr Noblett notedthat the CardioQ is now established as a standard of care in patients undergoingbowel surgery at the Freeman hospital, under both open and minimally invasivesurgery. Deltex Medical's Chief Executive, Andy Hill commented: "These results are highly relevant to the US market, confirming that the CardioQprovides substantial benefits to those patients who are being treated using thelatest minimally invasive surgical techniques. "It has long been established that the CardioQ delivers significant clinical andeconomic benefits when introduced into traditional approaches to surgery. Theimpact of combining CardioQ with keyhole surgery within an enhanced recoveryprogramme is revolutionary. Outcomes from the Freeman bowel surgery programmeare truly world-class: it has dramatically reduced complication rates, all buteliminated readmissions and substantially reduced lengths of stay." For further information, please contact:- Deltex Medical Group plc 01243 774 837Nigel Keen, Chairman njk@deltexmedical.comAndy Hill, Chief Executive ahill@deltexmedical.comEwan Phillips, Finance Director eap@deltexmedical.com Gavin Anderson & Company 0207 554 1400Deborah Walter dwalter@gavinanderson.co.ukRobert Speed rspeed@gavinanderson.co.uk Charles Stanley Securities 020 7149 6457Philip Davies philip.davies@csysecurities.comRussell Cook russell.cook@csysecurities.com Notes for Editors Deltex Medical manufactures and markets the CardioQ monitor, which usesdisposable ultra-sound probes inserted into the oesophagus to determine theamount of blood being pumped around the body - 'circulating blood volume'.Reduced circulating blood volume is known as hypovolaemia, which leads toinsufficient oxygen being delivered to the organs. This causes medicalcomplications including peripheral and major organ failure which can lead todeath. Hypovolaemia, which is akin to severe dehydration, affects virtuallyevery patient having surgery because of the combined effects of pre-operativestarvation, the impact of the anaesthetic agents and trauma from the surgeryitself. Using fluids and drugs, guided by the CardioQ, to optimise the amount ofcirculating blood significantly reduces post-operative complications allowingpatients to make a faster, more complete recovery and return home earlier. The CardioQ incorporates the Company's proprietary software and a smalldiameter, easy-to-use, minimally invasive, disposable oesophageal probe that isused for transmitting and receiving an ultra-sound signal. By using thistechnology, the CardioQ provides clinicians with the ability to haemodynamicallyoptimise critically ill patients and those undergoing routine moderate to majorsurgery through the controlled administration of fluid and drugs. Haemodynamicoptimisation has been scientifically proven to improve the speed and quality ofpatient recovery and reduce hospital stay. There are already over 1,250 CardioQs currently in use in hospitals worldwideand distribution arrangements are in place in over 30 countries. In addition,there are currently more than 90 clinical publications on the use of the CardioQwhich have repeatedly:- •Validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works •Proved that the CardioQ works in a wide range of surgical procedures •Demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. The SupraQ is an entirely non-invasive device which uses an ultrasound probeheld at the base of the patient's neck to track the flow of blood in the aorta;it presents the same data as the CardioQ in a similar format and is used fortaking snapshots or monitoring over short periods. This information is provided by RNS The company news service from the London Stock Exchange